New chief development officer named at MorphoSys

Germany-based MorphoSys (FSE: MOR) has appointed Dr Malte Peters as chief development officer.

Dr Peters will take up the position on March 1, 2017 and will succeed Dr Arndt Schottelius, who is leaving to pursue other opportunities. Dr Peters joins MorphoSys from Sandoz, the generics and biosimilars business of Swiss giant major Novartis (NOVN: VX), where he serves as global head, clinical development biopharmaceuticals.

Dr Peters built his career in early and late-stage clinical development over the last 18 years. Prior to his latest role at Sandoz, he spent 12 years in various managerial positions within Novartis focusing on management of clinical development projects in oncology. Before that, Dr Peters served in positions as medical director at Micromet and as head of translational research and pharmacogenomics at Merck KGaA.